Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...

We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...

Johnson & Johnson MedTech has announced U.S. 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...